Condition (MeSH)
Hepatitis A
ClinicalTrials.gov lists 81 trials for Hepatitis A or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 27.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
81 of the 81 trials are tagged with Hepatitis A itself; the rest are tagged with a narrower condition beneath it.
When did Hepatitis A trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 4 |
| 2015 | 3 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hepatitis A trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 20 |
| Phase 4 | 32 |
| Not applicable | 5 |
| Observational | 17 |
How many Hepatitis A trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 1 |
| Active, not recruiting | 3 |
| Completed | 59 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hepatitis A trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 27 |
| Sinovac Biotech Co., Ltd | 7 |
| Sanofi Pasteur, a Sanofi Company | 6 |
| Crucell Holland BV | 3 |
| Centers for Disease Control and Prevention | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Hepatitis A? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| VAQTA | 5 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Havrix+Havrix | 12 |
| hepatitis A (HAV) vaccines | 8 |
| Engerix™ | 5 |
| Blood Sampling | 5 |
| TWINRIX | 5 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hepatitis A trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile convulsion | 21 | 2 |
| Gastroenteritis | 21 | 4 |
| Pneumonia | 19 | 4 |
| Bronchiolitis | 6 | 3 |
| Bronchitis | 6 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Hepatitis A? (91)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Vaccination status and hepatitis A immunity in children: insights from a large-scale study in Turkey. | BMC infectious diseases | 2025 | Yes |
| Hepato-selective dihydroquinolizinones active against hepatitis A virus in vitro and in vivo. | Antiviral research | 2025 | Yes |
| Seroprevalence of hepatitis A virus antibodies among children and adolescents living in Northern Thailand: an implication for hepatitis A immunization. | Scientific reports | 2023 | Yes |
| Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection. | Hepatology international | 2023 | Yes |
| A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. | Vaccine | 2023 | Yes |
Showing 5 of 91 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.